CY1119324T1 - Αντισωματα εναντιον csf-1r - Google Patents
Αντισωματα εναντιον csf-1rInfo
- Publication number
- CY1119324T1 CY1119324T1 CY20171100949T CY171100949T CY1119324T1 CY 1119324 T1 CY1119324 T1 CY 1119324T1 CY 20171100949 T CY20171100949 T CY 20171100949T CY 171100949 T CY171100949 T CY 171100949T CY 1119324 T1 CY1119324 T1 CY 1119324T1
- Authority
- CY
- Cyprus
- Prior art keywords
- csf
- antibodies
- antibodies against
- against csf
- internalizing
- Prior art date
Links
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 title abstract 3
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 title abstract 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010014733 Endometrial cancer Diseases 0.000 abstract 1
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 abstract 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 229960003668 docetaxel Drugs 0.000 abstract 1
- 229960004679 doxorubicin Drugs 0.000 abstract 1
- 230000002357 endometrial effect Effects 0.000 abstract 1
- 229940022353 herceptin Drugs 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 210000002540 macrophage Anatomy 0.000 abstract 1
- 210000001616 monocyte Anatomy 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31989610P | 2010-04-01 | 2010-04-01 | |
| PCT/US2011/030148 WO2011123381A1 (en) | 2010-04-01 | 2011-03-28 | Antibodies against csf-1r |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119324T1 true CY1119324T1 (el) | 2018-02-14 |
Family
ID=44010222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100949T CY1119324T1 (el) | 2010-04-01 | 2017-09-07 | Αντισωματα εναντιον csf-1r |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8263079B2 (OSRAM) |
| EP (2) | EP3156419A1 (OSRAM) |
| JP (1) | JP5767310B2 (OSRAM) |
| KR (1) | KR101439719B1 (OSRAM) |
| CN (1) | CN102834414B (OSRAM) |
| AR (1) | AR080698A1 (OSRAM) |
| AU (1) | AU2011232850B2 (OSRAM) |
| BR (1) | BR112012024564A2 (OSRAM) |
| CA (1) | CA2795081C (OSRAM) |
| CY (1) | CY1119324T1 (OSRAM) |
| DK (1) | DK2552966T3 (OSRAM) |
| EA (1) | EA021600B1 (OSRAM) |
| ES (1) | ES2640909T3 (OSRAM) |
| HR (1) | HRP20171153T1 (OSRAM) |
| HU (1) | HUE036379T2 (OSRAM) |
| IL (1) | IL222222A (OSRAM) |
| JO (1) | JO3291B1 (OSRAM) |
| LT (1) | LT2552966T (OSRAM) |
| ME (1) | ME02806B (OSRAM) |
| MX (1) | MX2012011234A (OSRAM) |
| NZ (1) | NZ602621A (OSRAM) |
| PL (1) | PL2552966T3 (OSRAM) |
| PT (1) | PT2552966T (OSRAM) |
| RS (1) | RS56219B1 (OSRAM) |
| SG (1) | SG183829A1 (OSRAM) |
| SI (1) | SI2552966T1 (OSRAM) |
| TW (1) | TWI402078B (OSRAM) |
| UA (1) | UA111818C2 (OSRAM) |
| WO (1) | WO2011123381A1 (OSRAM) |
| ZA (1) | ZA201206926B (OSRAM) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS58693B1 (sr) | 2009-12-10 | 2019-06-28 | Hoffmann La Roche | Antitela koja poželjno vezuju ekstracelularni domen 4 humanog csf1r, i njihova primena |
| US10487148B2 (en) | 2010-01-28 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated impairments |
| US20160208011A1 (en) | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
| US10626399B2 (en) | 2010-01-28 | 2020-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3) |
| BR112012020372A8 (pt) | 2010-03-05 | 2018-01-02 | Hoffmann La Roche | anticorpo que se liga ao csf-1r humano, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira e método para a produção de um anticorpo recombinante |
| CA2789071C (en) | 2010-03-05 | 2018-03-27 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
| KR20200044999A (ko) | 2010-05-04 | 2020-04-29 | 파이브 프라임 테라퓨틱스, 인크. | Ｃｓｆ1ｒ에 결합하는 항체들 |
| US9161968B2 (en) | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
| US10023643B2 (en) | 2011-12-15 | 2018-07-17 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
| BR112014018961A8 (pt) * | 2012-02-06 | 2017-07-11 | Genentech Inc | Anticorpo isolado, anticorpo biespecífico, fragmento, ácido nucleico isolado, vetor, célula hospedeira, método de produção de anticorpos, composição farmacêutica, uso do anticorpo, método de tratamento, método de inibição e artigo industrializado |
| AR090263A1 (es) * | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| AR095882A1 (es) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
| GB201315487D0 (en) | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| WO2015088915A1 (en) | 2013-12-09 | 2015-06-18 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated conditions |
| US10905779B2 (en) | 2013-12-09 | 2021-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening human blood products comprising plasma using immunocompromised rodent models |
| KR102000224B1 (ko) * | 2014-02-03 | 2019-07-16 | 전대연 | 스마트 이메일 관리방법 |
| SG11201610672YA (en) | 2014-06-23 | 2017-01-27 | Five Prime Therapeutics Inc | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| KR102636539B1 (ko) | 2014-10-29 | 2024-02-13 | 파이브 프라임 테라퓨틱스, 인크. | 암에 대한 조합 요법 |
| BR112017013111A2 (pt) | 2014-12-22 | 2018-05-15 | Five Prime Therapeutics Inc | métodos de tratamento de um distúrbio e de tratamento da sinovite, uso de um anticorpo e anticorpo |
| SMT202100132T1 (it) | 2015-04-13 | 2021-05-07 | Five Prime Therapeutics Inc | Terapia di combinazione per il cancro |
| EP3303390A1 (en) | 2015-05-27 | 2018-04-11 | UCB Biopharma SPRL | Method for the treatment of neurological disease |
| ES2902467T3 (es) | 2015-06-15 | 2022-03-28 | Univ Leland Stanford Junior | TIMP2 para su uso en el tratamiento de afecciones asociadas al envejecimiento |
| JP6621252B2 (ja) * | 2015-06-17 | 2019-12-18 | 国立大学法人北海道大学 | 治療耐性がんに対する治療耐性低減剤 |
| EP3108897A1 (en) | 2015-06-24 | 2016-12-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias |
| MX2017016651A (es) * | 2015-06-24 | 2018-05-14 | Hoffmann La Roche | Anticuerpos contra csf-1r humano para su uso en la induccion de linfocitosis en linfomas o leucemias. |
| WO2017079520A1 (en) | 2015-11-04 | 2017-05-11 | Duke University | Combination therapy of immunotoxin and checkpoint inhibitor |
| WO2017085566A1 (en) * | 2015-11-20 | 2017-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for increase/induction of immune responses |
| CN108350080A (zh) * | 2015-11-24 | 2018-07-31 | 伊莱利利公司 | 用于癌症的联合疗法 |
| MA44309A (fr) * | 2015-11-25 | 2018-10-03 | Nogra Pharma Ltd | Oligonucléotides antisens il-34 et leurs procédés d'utilisation |
| EP3995141B1 (en) | 2016-04-28 | 2024-01-03 | Alkahest, Inc. | Plasma fractions as therapy for thymic cancer |
| CA3026474A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
| US10525107B2 (en) | 2016-08-18 | 2020-01-07 | Alkahest, Inc. | Blood plasma fractions as a treatment for aging-associated cognitive disorders |
| JP7138094B2 (ja) | 2016-08-25 | 2022-09-15 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与 |
| TW201825519A (zh) | 2016-10-18 | 2018-07-16 | 美商美國禮來大藥廠 | TGFβ受體II抗體 |
| JP7304287B2 (ja) * | 2016-12-22 | 2023-07-06 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療 |
| WO2018144334A1 (en) | 2017-02-02 | 2018-08-09 | Imclone Llc | Dosing regimen for anti-csf-1r antibody |
| WO2018183366A1 (en) | 2017-03-28 | 2018-10-04 | Syndax Pharmaceuticals, Inc. | Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy |
| CA3058944A1 (en) | 2017-04-19 | 2018-10-25 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| US11040068B2 (en) | 2017-04-26 | 2021-06-22 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| AU2018257921B2 (en) | 2017-04-26 | 2024-06-06 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| JP7537874B2 (ja) | 2017-05-19 | 2024-08-21 | シンダックス ファーマシューティカルズ， インコーポレイテッド | 併用療法 |
| PE20200797A1 (es) | 2017-08-25 | 2020-08-10 | Five Prime Therapeutics Inc | Anticuerpos que se unen especificamente a b7-h4 humana |
| WO2019055537A1 (en) | 2017-09-13 | 2019-03-21 | Five Prime Therapeutics, Inc. | ANTI-CSF1R AND ANTI-PD -1 ANTIBODY POLYTHERAPY FOR PANCREATIC CANCER |
| WO2019113464A1 (en) | 2017-12-08 | 2019-06-13 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| BR112020016986A2 (pt) | 2018-02-21 | 2021-03-02 | Five Prime Therapeutics, Inc. | formulações de anticorpo contra b7-h4 |
| GB201803226D0 (en) | 2018-02-28 | 2018-04-11 | Ultrahuman Twelve Ltd | CSF1R Binding agents |
| CA3091801A1 (en) | 2018-03-02 | 2019-09-06 | Five Prime Therapeutics, Inc. | B7-h4 antibodies and methods of use thereof |
| WO2019191295A1 (en) * | 2018-03-28 | 2019-10-03 | Bristol-Myers Squibb Company | Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use |
| MX2020012567A (es) * | 2018-05-23 | 2021-01-29 | Beigene Ltd | Anticuerpos anti-ox40 y metodos de uso. |
| CN108948200B (zh) * | 2018-07-18 | 2019-05-10 | 博奥信生物技术（南京）有限公司 | 一种抗人csf-1r单克隆抗体及其应用 |
| CN109096397B (zh) * | 2018-07-18 | 2019-04-16 | 博奥信生物技术（南京）有限公司 | 一种抗人csf-1r单克隆抗体及应用 |
| CN108948201B (zh) * | 2018-07-18 | 2019-05-07 | 博奥信生物技术（南京）有限公司 | 抗人csf-1r单克隆抗体及应用 |
| AU2019310597A1 (en) * | 2018-07-27 | 2021-03-11 | Alector Llc | Anti-siglec-5 antibodies and methods of use thereof |
| CA3113826A1 (en) | 2018-09-27 | 2020-04-02 | Marengo Therapeutics, Inc. | Csf1r/ccr2 multispecific antibodies |
| MX2021004755A (es) | 2018-10-26 | 2021-06-08 | Alkahest Inc | Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria. |
| US12043668B2 (en) | 2018-12-13 | 2024-07-23 | Development Center For Biotechnology | Anti-human CSF-1R antibody and uses thereof |
| ES2984122T3 (es) * | 2019-03-05 | 2024-10-29 | Inserm Institut National De La Santeet De La Rech Medicale | Biomarcadores para carcinoma de células renales |
| WO2020232051A1 (en) * | 2019-05-15 | 2020-11-19 | Biosion Inc. | Antibody binding csf-1r and use thereof |
| CN113811331A (zh) * | 2019-05-24 | 2021-12-17 | 安立玺荣生医(香港)有限公司 | 抗csf1r抗体、il10融合蛋白及其用途 |
| CN110499295A (zh) * | 2019-09-11 | 2019-11-26 | 宝船生物医药科技(上海)有限公司 | 一种csf-1r报告基因细胞株及其制备方法和应用 |
| JP7712917B2 (ja) | 2019-09-26 | 2025-07-24 | エフ． ホフマン－ラ ロシュ アーゲー | 抗ｃｓｆ－１ｒ抗体 |
| JP7513709B2 (ja) * | 2019-10-17 | 2024-07-09 | ナショナル ヘルス リサーチ インスティテューツ | 抗コハク酸モノクローナル抗体およびヒト化抗コハク酸抗体 |
| KR102373965B1 (ko) * | 2020-06-05 | 2022-03-15 | (주)지아이이노베이션 | Ｉｌ-２ 단백질 및 ｃｄ８０ 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물 |
| CN115806626B (zh) * | 2022-06-21 | 2024-02-23 | 四川大学华西医院 | 一种基于csf1的嵌合抗原受体免疫细胞制备及其应用 |
| TW202446418A (zh) | 2023-05-17 | 2024-12-01 | 美商錫達斯醫藥股份有限公司 | 使用抗群落刺激因子１受體抗體治療慢性移植物抗宿主病相關閉塞性細支氣管炎症候群之方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IL89489A0 (en) | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
| JPH02503867A (ja) | 1988-04-15 | 1990-11-15 | プロテイン デザイン ラブズ インコーポレーテッド | Ｉｌ‐２レセプター特異的キメラ抗体 |
| JP3105898B2 (ja) | 1988-04-16 | 2000-11-06 | セルテック リミテッド | 組換えｄｎａタンパクの製造方法 |
| JPH0967400A (ja) | 1995-08-31 | 1997-03-11 | Toray Ind Inc | モノクローナル抗体、該抗体を産生するハイブリドーマ及びその利用 |
| WO2004045532A2 (en) * | 2002-11-15 | 2004-06-03 | Chiron Corporation | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| NZ560844A (en) | 2005-03-08 | 2008-08-29 | Pharmacia & Upjohn Co Llc | Anti-MAdCAM antibody compositions |
| TWI595005B (zh) * | 2007-08-21 | 2017-08-11 | 安健股份有限公司 | 人類ｃ－ｆｍｓ抗原結合蛋白質 |
| KR101633520B1 (ko) | 2008-03-14 | 2016-06-24 | 트랜스진 에스.에이. | Ｃｓｆ－１ｒ에 대한 항체 |
-
2011
- 2011-03-21 AR ARP110100905A patent/AR080698A1/es unknown
- 2011-03-22 JO JOP/2011/0097A patent/JO3291B1/ar active
- 2011-03-25 TW TW100110442A patent/TWI402078B/zh not_active IP Right Cessation
- 2011-03-28 ME MEP-2017-174A patent/ME02806B/me unknown
- 2011-03-28 ES ES11713416.3T patent/ES2640909T3/es active Active
- 2011-03-28 BR BR112012024564A patent/BR112012024564A2/pt not_active Application Discontinuation
- 2011-03-28 MX MX2012011234A patent/MX2012011234A/es active IP Right Grant
- 2011-03-28 KR KR1020127025707A patent/KR101439719B1/ko not_active Expired - Fee Related
- 2011-03-28 HR HRP20171153TT patent/HRP20171153T1/hr unknown
- 2011-03-28 JP JP2013502691A patent/JP5767310B2/ja not_active Expired - Fee Related
- 2011-03-28 DK DK11713416.3T patent/DK2552966T3/en active
- 2011-03-28 AU AU2011232850A patent/AU2011232850B2/en not_active Ceased
- 2011-03-28 SI SI201131235T patent/SI2552966T1/sl unknown
- 2011-03-28 NZ NZ602621A patent/NZ602621A/en not_active IP Right Cessation
- 2011-03-28 EA EA201270732A patent/EA021600B1/ru not_active IP Right Cessation
- 2011-03-28 UA UAA201210763A patent/UA111818C2/uk unknown
- 2011-03-28 WO PCT/US2011/030148 patent/WO2011123381A1/en not_active Ceased
- 2011-03-28 CN CN201180017294.3A patent/CN102834414B/zh not_active Expired - Fee Related
- 2011-03-28 LT LTEP11713416.3T patent/LT2552966T/lt unknown
- 2011-03-28 US US13/073,004 patent/US8263079B2/en not_active Expired - Fee Related
- 2011-03-28 PL PL11713416T patent/PL2552966T3/pl unknown
- 2011-03-28 EP EP16196811.0A patent/EP3156419A1/en not_active Withdrawn
- 2011-03-28 RS RS20170817A patent/RS56219B1/sr unknown
- 2011-03-28 EP EP11713416.3A patent/EP2552966B1/en active Active
- 2011-03-28 CA CA2795081A patent/CA2795081C/en not_active Expired - Fee Related
- 2011-03-28 HU HUE11713416A patent/HUE036379T2/hu unknown
- 2011-03-28 SG SG2012064135A patent/SG183829A1/en unknown
- 2011-03-28 PT PT117134163T patent/PT2552966T/pt unknown
-
2012
- 2012-09-14 ZA ZA2012/06926A patent/ZA201206926B/en unknown
- 2012-09-27 IL IL222222A patent/IL222222A/en not_active IP Right Cessation
-
2017
- 2017-09-07 CY CY20171100949T patent/CY1119324T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119324T1 (el) | Αντισωματα εναντιον csf-1r | |
| CY1121546T1 (el) | Ανθρωποποιημενα αντισωματα εναντι liv-1 και χρηση των ιδιων στην αγωγη του καρκινου | |
| CY1119591T1 (el) | Πρωτεϊνες ειδικης συνδεσης και χρησεις αυτων | |
| UA110370C2 (en) | Conjugates of amatoxin with improved linkages | |
| CY1123983T1 (el) | Ειδικα σε axl συζευγματα αντισωματος-φαρμακου για τη θεραπεια καρκινου | |
| CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
| TN2015000396A1 (en) | Antibody drug conjugates | |
| CL2016002359A1 (es) | Anticuerpos que se une al receptor de crecimiento epidermal humano (anti-egfr) y conjugados de anticuerpo anti-egfr y fármaco | |
| CY1119251T1 (el) | Θεραπεια συνδυασμου ενος αφουκοζυλιωμενου αντισωματος cd20 με μπενδαμουστινη | |
| EA201691824A1 (ru) | АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ | |
| MX344010B (es) | Conjugados de amatoxina con enlazantes mejorados. | |
| CO6612264A2 (es) | Proteinas terapeuticas de la union a dll 4 | |
| MX2015012122A (es) | Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes. | |
| MX374463B (es) | Anticuerpos anti-egfr y usos de los mismos. | |
| PH12014501039B1 (en) | Cytotoxic peptides and antibody drug conjugates thereof | |
| MX2016012094A (es) | Composiciones de anticuerpos para tratamiento tumoral. | |
| EA201390472A1 (ru) | Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты | |
| MX341076B (es) | Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados. | |
| MX2020006116A (es) | Terapia combinada de agonistas de icos dirigidos a tumores con moleculas biespecificas de linfocitos t. | |
| BR112015027309A2 (pt) | anticorpo, composição, método de tratamento e uso de um anticorpo | |
| EA201101651A1 (ru) | Непрерывное введение интегриновых лигандов для лечения рака | |
| CY1121667T1 (el) | Παραγοντες για θεραπεια τριπλα αρνητικου καρκινου μαστου | |
| MX2016001541A (es) | Uso de anticuerpo inmunoconjugado anti-muc1 maitansinoide para el tratamiento de tumores solidos. | |
| IL269655A (en) | Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour | |
| TR201905240T4 (tr) | LIV-1'e hümanize edilmiş antikorlar ve bunların kanserin tedavisinde kullanımı. |